注冊

結(jié)腸癌qBiomarker體細(xì)胞突變PCR芯片 Colon Cancer qBiomarker Mutation PCR Array

科技服務(wù) > 生物芯片實(shí)驗(yàn)服務(wù) > 結(jié)腸癌qBiomarker體細(xì)胞突變PCR芯片 Colon Cancer qBiomarker Mutation PCR Array

結(jié)腸癌qBiomarker體細(xì)胞突變PCR芯片 Colon Cancer qBiomarker Mutation PCR Array

聯(lián)系購買

配送服務(wù)：

運(yùn)費(fèi) ￥0.00

數(shù)量：

（庫存 9999 件）

產(chǎn)品詳細(xì)

簡介：	Colon Cancer qBiomarker Mutation PCR Array 結(jié)腸癌qBiomarker體細(xì)胞突變PCR芯片
提供商：	SAbiosciences
服務(wù)名稱：	結(jié)腸癌qBiomarker體細(xì)胞突變PCR芯片
地區(qū)：	美國

“英拜為您實(shí)驗(yàn)加速”
技術(shù)服務(wù)網(wǎng)址：http://bhsflw.cn/
服務(wù)熱線：400-696-6643、 18019265738
郵箱：daihp@yingbio.com 、 huizhang1228@foxmail.com

Colon Cancer qBiomarker Mutation PCR Array

結(jié)腸癌qBiomarker體細(xì)胞突變PCR芯片

Product	Species	Technology	Cat. No.
Colon Cancer qBiomarker Mutation PCR Array	Human	Somatic Mutation	SMH-021A

The Human Colon Cancer qBiomarker Somatic Mutation PCR Array is a translational research tool that allows rapid, accurate, and comprehensive profiling of the top somatic mutations in human colon cancer samples in the following genes: APC, BRAF, CTNNB1/beta-catenin, FBXW7, KRAS, PIK3CA, SRC, and P53. These mutations warrant extensive investigation to enhance the understanding of carcinogenesis and identify potential drug targets. Numerous research studies have demonstrated the utility of individual and multiple somatic mutation status information in identifying key signaling transduction disruptions. For example, the mutation status of the EGFR and KRAS genes can predict the physiological response to certain drugs targeting these molecules. The Human Colon Cancer qBiomarker Somatic Mutation PCR Array, with its comprehensive content coverage, is designed for the study of mutations in the context of colon cancer and has the potential for discovery and verification of drug target biomarkers for this cancer type and other cancer types in which these mutations have been identified. This array includes 86 DNA sequence mutation assays designed to detect the most frequent, functionally verified, and biologically significant mutations in human colon cancer. These mutations were chosen from curated, comprehensive somatic mutation databases and peer-reviewed scientific literature, and represent the most frequently recurring somatic mutations compiled from over 29,000 colon cancer samples. The simplicity of the product format and operating procedure allows routine somatic mutation profiling in any research laboratory with access to real-time PCR instruments.

結(jié)腸癌qBiomarker體細(xì)胞突變PCR芯片是一個(gè)翻譯研究的工具,允許快速、準(zhǔn)確、全面的分析在人類結(jié)腸癌樣本中前體細(xì)胞的基因突變:APC,BRAF,CTNNB1 /β-連環(huán)蛋白FBXW7, KRAS, PIK3CA, SRC, and P53。這些突變保證廣泛的研究,以提高致癌作用的理解和鑒定潛在的藥物靶點(diǎn)。已有許多研究通過單個(gè)和多個(gè)體細(xì)胞突變狀態(tài)信息鑒定關(guān)鍵信號轉(zhuǎn)導(dǎo)中斷。例如，EGFR和KRAS基因的突變狀態(tài)可以預(yù)測某些藥物針對這些分子的生理反應(yīng)。人類結(jié)腸癌qBiomarker體細(xì)胞突變PCR芯片以其全面的內(nèi)容覆蓋范圍，用于研究結(jié)腸癌背景下的基因突變,有可能發(fā)現(xiàn)和鑒定結(jié)腸癌和這些突變已確定的其他癌癥的藥物靶標(biāo)。這個(gè)芯片包含86個(gè)DNA突變序列用于檢測最頻繁的、能性驗(yàn)證、在人類結(jié)腸癌癥中有生物學(xué)意義的突變。這些突變的選擇根據(jù)全面的體細(xì)胞突變數(shù)據(jù)庫和同行評審的科學(xué)文獻(xiàn)，來自29,000多個(gè)結(jié)腸癌樣本發(fā)生最頻繁重復(fù)編譯的體細(xì)胞突變。簡單的產(chǎn)品模式和操作程序讓任何一個(gè)具備實(shí)時(shí)定量PCR儀的實(shí)驗(yàn)室都可進(jìn)行常規(guī)的體細(xì)胞突變分析。

APC: 34 Assays
The most commonly detected APC inactivation mutations are mainly composed of truncation mutations (due to nonsense mutations and frameshift mutations) and point mutations between codons 1250 and 1578.
BRAF: 1 Assay
In colon cancer, the BRAF mutation that leads to increased kinase activity, p. V600E mutation, is the most important to test.
CTNNB1: 5 Assays
The most frequently detected CTNNB1/beta-catenin mutations result in abnormal signaling in the WNT signaling pathway. The mutated codons are mainly several serine/threonine residues targeted for phosphorylation by GSK-3beta.
FBXW7: 1 Assay
The mutations queried by these assays lay in either the third or fourth repeat of the protein's WD40 domain, typically involved in protein-protein interactions.
KRAS: 17 Assays
The mutation assays include the most frequently occurring mutations in KRAS codons 12, 13, and 61. Mutations at these positions result in reduced intrinsic GTPase activity and/or cause KRAS to become unresponsive to RasGAP.
PIK3CA: 7 Assays
The most frequently occurring PIK3CA mutations mainly belong to two classes: gain-of-function kinase domain activating mutations and helical domain mutations that mimic activation by growth factors.
SRC: 1 Assay
SRC is a proto-oncogene and a tyrosine-protein kinase that plays a role in the regulation of embryonic development and cell growth. Mutations in this gene could be involved in the malignant progression of colon cancer.
TP53: 20 Assays
The most frequently detected somatic mutations in TP53 are largely composed of DNA-binding domain mutations which disrupt either DNA binding or protein structure.

工作原理：

Overview of the qBiomarker Somatic Mutation PCR Array / Assay Protocol

Overview of the qBiomarker Somatic Mutation PCR Array / Assay Protocol.
The procedure involves DNA extraction (QIAGEN QIAamp DNA Mini Kit or FFPE Tissue Kit is recommended), an optional amplification (QIAGEN REPLI-g kit or REPLI-g UltraFast kit is recommended) step for DNA isolated from fresh samples, qPCR detection on qBiomarker Somatic Mutation PCR Arrays or Assays, and data analysis (using the qBiomarker Somatic Mutation Data Analysis Template). An optional DNA sample QC step immediately before the detection array or assay setup allows the user to qualify the DNA samples.

Principle of Mutant Discrimination with ARMS?